March 31, 2025 8:07am

Last week; equities sold-off and during most of March, February and January; this week will the cell and gene therapy sector be liberated not likely?

Pre-empted by a weak pre-open and aftermarket after all the past 3 months downslides

Pre-Open Indications: 4 Negative Indications

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief …

I am NOT often wrong and always consider doubt of some market and sector share pricing movements

Never leave an investor uninform

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Friday’s night’s … RegMed Investors (RMi) Closing Bell:  the problem, we are always spectators… https://www.regmedinvestors.com/articles/13859

RegMed Investors (RMi) Research Note: The clock continues to tick down on Harvard Apparatus GT (OTCQB: HRGN) … https://www.regmedinvestors.com/articles/13812

 

Monday; the pre-open Dow futures are DOWN -0.66% or (-277 points), the S&P futures DOWN -1.07% or (-60 points) and the Nasdaq futures are DOWN -1.46% or (-283 points)

  • U.S. stock futures fell Monday as traders waited for “Liberation Day” for clarity on President Trump’s tariff plans,
  • European markets traded sharply lower,
  • Asia-Pacific markets plunged.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Friday: The Dow closed DOWN -715.80 points or -1.69%, the S&P closed DOWN -112.37 points or -1.97% while the Nasdaq closed DOWN -481.04 points or -2.70

Last week, the S&P 500 lost -1.53%, the Dow -0.96% while the Nasdaq declined by -2.59%.

On Friday, the CBOE Volatility Index (VIX) soared nearly 20% from its close on Thursday, touching a lunchtime high of 22.18, which was only the highest absolute level since March 18 and the largest percentage (%) increase since March 10.

  • The VIX this month soared as high as 29.57 during a market sell-off on March 11, after ending February at 19.63. The VIX low for the month of March came earlier this week, on Wednesday March 26, after a three-day rebound in stocks drove the index down to 16.97. <CNBC>

Economic Data Docket: Economic growth in the first quarter was just 0.3%, according to CNBC’s Rapid Update which tallied the forecasts of 14 economists. The survey also shows Core PCE inflation will remain stuck at around 2.9% for most of the year.

  • The dour forecasts come as the decline in consumer and business sentiment from the tariff trade war is showing up in real economic activity.
  • The “BIG One” is Friday, March jobs report, which will be released at 8:30 a.m. ET on Friday, 4/4.

 

Q1/25 – March, 10 positive and 11 negative closes

  • February – 12 holiday, 11 negative and 7 positive closes
  • January - 2 holidays, 1 market close, 10 negative and 10 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Negative Indications:

  • Alnylam Pharmaceuticals (ALNY) closed down -$2.56 with a negative -2.46 or -0.92%
  • CRISPR Therapeutics (CRSP) closed down -$1.05 with a negative $1.54 or -4.16%
  • Moderna (MRNA) closed down -$1.00 after Thursday’s +$0.64 after Wednesday’s -$2.37 with a negative -4.38 or -14.07%
  • Ultragenyx Pharmaceuticals (RARE) closed down -$1.07 with a negative $0.02 or -0.05% aftermarket

 

The BOTTOM LINE:  Head down, ears covered, eyes on a swivel  

Think about it; one of the biggest problems with the cell and gene therapy sector’s share pricing is …  99% of them have no earnings! If rates are higher for longer, that means that sector companies will continue to struggle or be unable to raise capital.

I think speculative behavior in this current market has ascended to a level beyond common sense

Merger and acquisition (M&A) activity; sector companies will seek opportunities to sell to better financed companies that can "deal with these additional costs associated of R&D and escalating SG&A.”

NOT much has changed, as I have written, “uncle algo and his trading dwarfs” determine the heights or lows of share pricing”

March ‘25: understand the “flow” …

  • 3/28 – Friday closed negative with 2 positive, 31 negative and 2 flats
  • 3/27 – Thursday closed positive with 22 positive, 10 negative and 3 flats
  • 3/26 – Wednesday closed negative with 3 positive, 28 negative and 4 flats
  • 3/25 - Tuesday closed negative with 7 positive, 25 negative and 3 flats
  • 3/24 - Monday closed positive with 31 positive, 3 negative and 1 flat
  • 3/21 – Friday closed negative with 17 positive, 16 negative and 2 flats
  • 3/20 – Thursday closed negative with 10 positive, 23 negative and 2 flats
  • 3/18 -Tuesday closed negative with 7 positive, 27 negative and 1 flat
  • 3/19 - Wednesday closed positive with 25 positive, 8 negative and 2 flats
  • 3/17 – Monday closed positive with 24 positive, 10 negative and 1 flat
  • 3/14 – Friday closed positive with 20 positive, 13 negative and 2 flats
  • 3/13 - Thursday closed negative with 4 positive, 30 negative and 1 flat
  • 3/12 – Wednesday closed positive with 25 positive, 9 negative and 1 flat
  • 3/11 – Tuesday closed positive with 23 positive, 11 negative and 1 flat
  • 3/10 – Monday closed negative with 3 positive, 31 negative and 1 flat
  • 3/7 - Friday closed negative with 14 positive, 17 negative and 4 flats
  • 3/6 – Thursday closed negative with 16 positive, 18 negative and 1 flat
  • 3/5 – Wednesday closed positive with 25 positive, 9 negative and 1 flat
  • 3/4 – Tuesday closed negative with 15 positive, 18 negative and 2 flats
  • 3/3 – Monday closed negative with 2 positive, 31 negative and 2 flats

 

What could 2025 have in store for the capital access space as Partners are the gift of life!

  • "You'll see a number of cell and gene therapy comandantes drive for secondaries – they’re desperate for cash, but I do think a lot of cell and gene therapy sector companies NEED to be focused on what is driving their own growth —they're focused on a lot of change BUT … that's happening in the market… capital expansion is second.

I seem to be asking a question followed by a question …

  • Do we need to brace ourself for more economics and their down trending affect?
  • Is this market STILL “bubblicious” my concerns are macroeconomic and valuation

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.